Skip to main content
. Author manuscript; available in PMC: 2015 Jul 9.
Published in final edited form as: Vaccine. 2013 Jul 31;31(40):4382–4388. doi: 10.1016/j.vaccine.2013.07.002

Fig. 1. Purification and functional analysis of recombinant proteins.

Fig. 1

(a) Coomassie-stained SDS-PAGE gel of recombinant DBPII variants and PvMSP1-19 purified by affinity chromatography on Ni+ column. (b) Differential mobility of refolded rDBPII antigens on SDS-PAGE gel before (−) and after (+) reduction with DTT. (c) Western blot analysis of rDBPII probed with conformation dependent mAb-2D10, shows antibody reacting with refolded (−) but not reduced (+) antigens. (d) Erythrocyte binding assay showing binding of refolded antigens to Duffy positive erythrocytes (+) and reduced or no binding with chymotrypsin-treated Duffy positive erythrocytes (−). Duffy positive erythrocytes incubated with PvMSP1-19 and PfAMA-1 and erythrocytes without bound antigen were used as negative controls.